PLX-4545

Overview

PLX-4545 is an investigational IKZF2 (Helios) degrader designed to reprogram regulatory T cells (Tregs) by eliminating the transcription factor that stabilizes Treg suppressive function. It is evaluated in nasopharyngeal carcinoma (NPC) and other solid tumors.

Evidence in the corpus

• PLX-4545 IKZF2 degrader listed alongside DKY709 as clinical-stage agents targeting IKZF2 (Helios) to reprogram Tregs in the immunosuppressive NPC tumor microenvironment PMID:24952746.

Resistance mechanisms

Cancer types (linked)

• NPC

Sources

This page was processed by entity-page-writer on 2026-05-11.